CareDx (CDNA) announced on April 15 that it entered into a definitive agreement to divest its Lab Products business to EuroBio Scientific, which is expected to close by the end of the third quarter of 2026. CareDx’s Lab Products business consists of IVD PCR kits for rapid deceased donor HLA typing, IVD NGS-based kits for transplant recipient HLA typing globally, including AlloSeq Nano; and IVD NGS-based monitoring assays for solid organ and stem cell transplant recipients outside of North America.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CDNA:
- CareDx Divests Lab Products to Refocus on Core Growth
- Closing Bell Movers: JB Hunt up 2% after Q1 earnings beat
- CareDx up 20% at $21 after Q1 pre-announcement, Lab Products divestment
- CareDx to divest Lab Products unit to EuroBio for $170M cash consideration
- CareDx reports preliminary Q1 revenue roughly $118M, consensus $102.49M